ZyVersa Therapeutics Inc (ZVSA)

1.19 -0.04 (-3.05%) USD  |  NASDAQ  |  Jan 08, 13:00
More

ZyVersa Therapeutics Research and Development Expense (Annual): 3.208M for Dec. 31, 2023

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for ZVSA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
MetaVia Inc 9.158M
Dermata Therapeutics Inc 4.070M
Cognition Therapeutics Inc 37.20M
NovaBay Pharmaceuticals Inc 0.068M
Palatin Technologies Inc 22.40M